The National Medical Products Administration has approved one new innovative drug for marketing.

Recently, the National Medical Products Administration approved the application of Sanofi Guoke Pharmaceutical Co., Ltd. to market the Anmiquitab single injection. This product is used for the treatment of moderate to severe plaque psoriasis in adults suitable for systemic treatment or phototherapy. The market of this product provides a new treatment option for relevant patients.